Cipargamin

Novartis 

Product vision
  • Uncomplicated malaria treatment for single-exposure radical cure (SERC) and/or resistance management
  • Severe malaria treatment
MoA
  • PfATP4 inhibitor
Key features
  • Novel mechanism of action
  • Very rapid killing of parasites
  • 75mg human dose stays above Minimal Parasiticidal Concentration for >8 days
  • Potential for transmission-blocking activity in a Standard Membrane Feeding Assay
Challenges
  • Safety profile to be further characterized in malaria patient study

Status
  • Phase II malaria patient study started in February 2018

  • Parenteral GLP safety study in progress

Next milestone
  • Phase II malaria patient study completion with oral formulation
  • Initiate first-in-human study with parenteral formulation
Previously
  • Names NITD609, KAE609: discovery partnership between MMV, Wellcome Trust, Novartis, and the Swiss TPH

MMV Project Director
  • Dr Gonzalo Acuña